WO2006028962A3 - 1-alkoxy 1h-imidazo ring systems and methods - Google Patents

1-alkoxy 1h-imidazo ring systems and methods Download PDF

Info

Publication number
WO2006028962A3
WO2006028962A3 PCT/US2005/031310 US2005031310W WO2006028962A3 WO 2006028962 A3 WO2006028962 A3 WO 2006028962A3 US 2005031310 W US2005031310 W US 2005031310W WO 2006028962 A3 WO2006028962 A3 WO 2006028962A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
alkoxy
ring systems
compounds
imidazo ring
Prior art date
Application number
PCT/US2005/031310
Other languages
French (fr)
Other versions
WO2006028962A2 (en
Inventor
Larry R Krepski
Daniel E Duffy
John F Gerster
Joan T Moseman
Original Assignee
3M Innovative Properties Co
Larry R Krepski
Daniel E Duffy
John F Gerster
Joan T Moseman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co, Larry R Krepski, Daniel E Duffy, John F Gerster, Joan T Moseman filed Critical 3M Innovative Properties Co
Priority to AU2005282726A priority Critical patent/AU2005282726B2/en
Priority to PL05794068T priority patent/PL1789042T3/en
Priority to AT05794068T priority patent/ATE555786T1/en
Priority to CA2578741A priority patent/CA2578741C/en
Priority to EP05794068A priority patent/EP1789042B1/en
Priority to US11/574,463 priority patent/US7579359B2/en
Priority to ES05794068T priority patent/ES2384390T3/en
Priority to JP2007530396A priority patent/JP5209312B2/en
Publication of WO2006028962A2 publication Critical patent/WO2006028962A2/en
Publication of WO2006028962A3 publication Critical patent/WO2006028962A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Imidazo-containing compounds (e.g., imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazotetrahydroquinolines) with an alkoxy substituent at the 1-position, pharmaceutical compositions containing the compounds and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
PCT/US2005/031310 2004-09-02 2005-09-01 1-alkoxy 1h-imidazo ring systems and methods WO2006028962A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2005282726A AU2005282726B2 (en) 2004-09-02 2005-09-01 1-alkoxy 1H-imidazo ring systems and methods
PL05794068T PL1789042T3 (en) 2004-09-02 2005-09-01 1-alkoxy 1h-imidazo ring systems and methods
AT05794068T ATE555786T1 (en) 2004-09-02 2005-09-01 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS
CA2578741A CA2578741C (en) 2004-09-02 2005-09-01 1-alkoxy 1h-imidazo ring systems and methods
EP05794068A EP1789042B1 (en) 2004-09-02 2005-09-01 1-alkoxy 1h-imidazo ring systems and methods
US11/574,463 US7579359B2 (en) 2004-09-02 2005-09-01 1-alkoxy 1H-imidazo ring systems and methods
ES05794068T ES2384390T3 (en) 2004-09-02 2005-09-01 1-alkoxy-1H-imidazo cyclic systems and associated methods
JP2007530396A JP5209312B2 (en) 2004-09-02 2005-09-01 1-alkoxy 1H-imidazo ring systems and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60662904P 2004-09-02 2004-09-02
US60/606,629 2004-09-02

Publications (2)

Publication Number Publication Date
WO2006028962A2 WO2006028962A2 (en) 2006-03-16
WO2006028962A3 true WO2006028962A3 (en) 2006-10-26

Family

ID=36036867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031310 WO2006028962A2 (en) 2004-09-02 2005-09-01 1-alkoxy 1h-imidazo ring systems and methods

Country Status (9)

Country Link
US (1) US7579359B2 (en)
EP (1) EP1789042B1 (en)
JP (1) JP5209312B2 (en)
AT (1) ATE555786T1 (en)
AU (1) AU2005282726B2 (en)
CA (1) CA2578741C (en)
ES (1) ES2384390T3 (en)
PL (1) PL1789042T3 (en)
WO (1) WO2006028962A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2536136C (en) 2003-08-27 2012-10-30 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
NZ546274A (en) 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
ES2392648T3 (en) 2004-12-30 2012-12-12 3M Innovative Properties Company Substituted chiral compounds containing a condensed 1,2-imidazo-4,5-c core
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2007120121A2 (en) 2005-02-09 2007-10-25 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
WO2006091394A2 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
EP1851224A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
CA2598656A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008531568A (en) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド Imidazonaphthyridine substituted with hydroxyalkyl
CA2598437A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1922317A4 (en) 2005-09-09 2009-04-15 Coley Pharm Group Inc Amide and carbamate derivatives of n-{2-ý4-amino-2- (ethoxymethyl)-1h-imidazoý4,5-c¨quinolin-1-yl¨-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
AU2006292119A1 (en) * 2005-09-23 2007-03-29 3M Innovative Properties Company Method for 1H-imidazo[4,5-c]pyridines and analogs thereof
AU2006311871B2 (en) 2005-11-04 2011-03-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
CN103582496B (en) 2011-06-03 2016-05-11 3M创新有限公司 There is the Heterobifunctional connection base of polyethylene glycol segment and the immune response modifier conjugate of being made by it
AU2012261959B2 (en) 2011-06-03 2015-12-03 Solventum Intellectual Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
EP3756669A1 (en) 2013-01-07 2020-12-30 The Trustees of the University of Pennsylvania Compositions for use for treating cutaneous t cell lymphoma
EP3344623B1 (en) * 2015-08-31 2021-02-17 3M Innovative Properties Company Imidazo[4,5-c]ring compounds containing substituted guanidine groups
JP6956070B2 (en) * 2015-08-31 2021-10-27 スリーエム イノベイティブ プロパティズ カンパニー Guanidine-substituted imidazole [4,5-c] cyclic compound
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
AR109629A1 (en) * 2016-09-08 2019-01-09 Medimmune Llc COMPOSITIONS FOR THE LOCAL ADMINISTRATION OF TOLL TYPE RECEIVER AGONISTS
EP3589631B1 (en) 2017-03-01 2021-07-21 3M Innovative Properties Company Imidazo[4,5-c]ring compounds containing guanidine substituted benzamide groups
JP7197244B2 (en) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー Amido-substituted imidazo[4,5-C]quinoline compounds with branched chain linking groups for use as immune response modifiers
JP2021516045A (en) 2018-02-28 2021-07-01 ファイザー・インク IL-15 variant and its use
AU2019274654B2 (en) 2018-05-23 2023-07-20 Pfizer Inc. Antibodies specific for CD3 and uses thereof
TWI803637B (en) 2018-05-23 2023-06-01 美商輝瑞大藥廠 Antibodies specific for gucy2c and uses thereof
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
KR20210141461A (en) * 2019-02-01 2021-11-23 캔웰 바이오테크 리미티드 Imidazoquinoline amine derivatives, pharmaceutical compositions, uses thereof
WO2021086689A1 (en) * 2019-10-29 2021-05-06 Prime Reach Trading Limited 4-amino-imidazoquinoline compounds and use thereof
WO2021124073A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
CN114901275A (en) * 2019-12-20 2022-08-12 纳米医疗有限公司 Formulated and/or co-formulated liposomal compositions containing Toll-like receptor ("TLR") agonist prodrugs useful for treating cancer and methods thereof
TW202216779A (en) 2020-07-17 2022-05-01 美商輝瑞股份有限公司 Therapeutic antibodies and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
DE69108920T2 (en) 1990-10-05 1995-11-30 Minnesota Mining & Mfg METHOD FOR PRODUCING IMIDAZO [4,5-C] QUINOLIN-4-AMINES.
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
EP0708772B1 (en) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
KR100518903B1 (en) 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Immune response modifier compounds for treatment of the th2 mediated and related diseases
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP0894797A4 (en) 1997-01-09 2001-08-16 Terumo Corp Novel amide derivatives and intermediates for the synthesis thereof
JPH1180156A (en) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd 1-(substitutedaryl)alkyl-1h-imidazopyridin-4-amine derivative
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
JPH11222432A (en) 1998-02-03 1999-08-17 Terumo Corp Preparation for external use containing amide derivative inducing interferon
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
CA2348741C (en) * 1998-10-30 2010-04-20 Nitromed Inc. Nitrosasted and nitrosylated nonsteroidal antiinflammatory compounds, comositions and methods of use
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
IL144028A0 (en) 1999-01-08 2002-04-21 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (en) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd Arachidonic acid-induced skin disease-treating agent
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
JP2005500510A (en) 2000-12-08 2005-01-06 スリーエム イノベイティブ プロパティズ カンパニー A screening method to identify compounds that selectively induce interferon alpha
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US20030133913A1 (en) 2001-08-30 2003-07-17 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
ES2367422T3 (en) 2001-10-09 2011-11-03 Amgen Inc. IMIDAZOL DERIVATIVES AS ANTI-INFLAMMATORY AGENTS.
EP1478371A4 (en) 2001-10-12 2007-11-07 Univ Iowa Res Found Methods and products for enhancing immune responses using imidazoquinoline compounds
DK1719511T3 (en) 2001-11-16 2009-04-14 Coley Pharm Group Inc N- [4- (4-amino-2-ethyl-1H-imidazo [4,5-c] quinolin-1-yl) butyl] methanesulfonamide, a pharmaceutical composition comprising the same, and use thereof
CA2467828C (en) 2001-11-29 2011-10-04 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1478327B1 (en) 2002-02-22 2015-04-29 Meda AB Method of reducing and treating uvb-induced immunosuppression
US20030185835A1 (en) * 2002-03-19 2003-10-02 Braun Ralph P. Adjuvant for vaccines
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
EP1513524A4 (en) 2002-06-07 2008-09-03 3M Innovative Properties Co Ether substituted imidazopyridines
CA2493227A1 (en) 2002-07-23 2004-01-29 Biogal Gyogyszergyar Rt. Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates
EP1539752B1 (en) 2002-07-26 2007-03-21 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via novel imidazo[4,5-c]quinolin-4-cyano and 1h-imidazo[4,5-c]quinolin-4-carboxamide intermediates
DK1545597T3 (en) 2002-08-15 2011-01-31 3M Innovative Properties Co Immune Stimulating Compositions and Methods for Stimulating an Immune Response
EP1542688A4 (en) 2002-09-26 2010-06-02 3M Innovative Properties Co 1h-imidazo dimers
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004053452A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
US7091214B2 (en) 2002-12-20 2006-08-15 3M Innovative Properties Co. Aryl substituted Imidazoquinolines
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co Selective modulation of tlr-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylactic treatment of uv-induced epidermal neoplasia
MY140539A (en) 2003-03-07 2009-12-31 3M Innovative Properties Co 1-amino 1h-imidazoquinolines
US7163947B2 (en) 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
US8426457B2 (en) 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
JP2006520245A (en) 2003-03-13 2006-09-07 スリーエム イノベイティブ プロパティズ カンパニー How to remove a tattoo
WO2004080293A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
JP2006523452A (en) 2003-03-25 2006-10-19 スリーエム イノベイティブ プロパティズ カンパニー Selective activation of cellular activity mediated through a common Toll-like receptor
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US7923560B2 (en) 2003-04-10 2011-04-12 3M Innovative Properties Company Delivery of immune response modifier compounds
US20040214851A1 (en) 2003-04-28 2004-10-28 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
BRPI0412902A (en) 2003-08-12 2006-09-26 3M Innovative Properties Co oxime-substituted imidazo-containing compounds
US7576068B2 (en) 2003-09-05 2009-08-18 Anadys Pharmaceuticals, Inc. Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
WO2005033049A2 (en) 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
ITMI20032121A1 (en) 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm PROCEDURE FOR THE PREPARATION OF IMIQUIMOD AND ITS INTERMEDIATES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUNDGAARD: "Design of Prodrugs", vol. CHAPTER1, 1985, ELSEVIER SCIENCE PUBLISHING, pages: 27 - 35, XP008057602 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods

Also Published As

Publication number Publication date
JP5209312B2 (en) 2013-06-12
JP2008511677A (en) 2008-04-17
AU2005282726B2 (en) 2011-06-02
PL1789042T3 (en) 2012-09-28
ES2384390T3 (en) 2012-07-04
US20090005376A1 (en) 2009-01-01
EP1789042A4 (en) 2009-07-22
ATE555786T1 (en) 2012-05-15
EP1789042B1 (en) 2012-05-02
CA2578741A1 (en) 2006-03-16
US7579359B2 (en) 2009-08-25
AU2005282726A1 (en) 2006-03-16
WO2006028962A2 (en) 2006-03-16
CA2578741C (en) 2014-01-14
EP1789042A2 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
WO2006028962A3 (en) 1-alkoxy 1h-imidazo ring systems and methods
WO2005018551A3 (en) Oxime substituted imidazo-containing compounds
WO2006038923A3 (en) Aryl substituted imidazonaphthyridines
WO2005048933A3 (en) Oxime substituted imidazo ring compounds
WO2005094531A3 (en) Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2006026760A3 (en) 1-amino imidazo-containing compounds and methods
WO2005048945A3 (en) Hydroxylamine substituted imidazo ring compounds
WO2005051317A3 (en) Substituted imidazo ring systems and methods
WO2005051324A3 (en) Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005123079A3 (en) Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2006086634A3 (en) Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006065280A3 (en) Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006029115A3 (en) 2-amino 1h imidazo ring systems and methods
WO2005032484A3 (en) Alkoxy substituted imidazoquinolines
MX2008002414A (en) Hydroxy substituted 1h-imidazopyridines and methods.
WO2007056112A3 (en) Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
WO2006086633A3 (en) Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods
WO2006074003A3 (en) CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
WO2006028545A3 (en) Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2007106852A3 (en) Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
WO2006091567A3 (en) Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2007106854A3 (en) Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2005076783A3 (en) Sulfone substituted imidazo ring ethers
MY145983A (en) Aryloxy and arylalkyleneoxy substituted imidazoquinolines
WO2006086449A3 (en) Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11574463

Country of ref document: US

Ref document number: 2578741

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007530396

Country of ref document: JP

Ref document number: 2005282726

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005794068

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005282726

Country of ref document: AU

Date of ref document: 20050901

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005282726

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005794068

Country of ref document: EP